Purdue announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets. Hysingla ER was approved in November 2014 for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment in patients for whom alternative treatment options are inadequate.
Hysingla ER, a Schedule II narcotic, is the first hydrocodone entity recognized as having abuse-deterrent properties that are expected to deter misuse and abuse via chewing, snorting, and injection. It incorporates the Company’s proprietary RESISTEC platform for extended-release solid oral dosage formulations. It uses unique polymer and processing that confers tablet hardness and viscosity when dissolved in aqueous solutions.
Hydrocodone binds to and activates opioid receptors in the brain and spinal cord, which are coupled to G-protein complexes and modulate synaptic transmission through adenylate cyclase. The pharmacological effects of hydrocodone including analgesia, euphoria, respiratory depression and physiological dependence are believed to be primarily mediated via mu-opioid receptors.
Hysingla ER is available in 20mg, 30mg, 40mg, 60mg, 80mg, 100mg, and 120mg strength tablets.
For more information call (888) 726-7535 or visit HysinglaER.com.